Re:Cognition Health

Fairfax, Virginia, United States
Mental health service in Merrifield, Virginia
8316 Arlington Blvd Suite 420, Fairfax, VA 22031

About Re:Cognition Health


"It’s cold and flu season. Feel better, faster with convenient walk-in family and urgent care. Open 7 days a week with extended hours - no appointment needed. Most insurance plans accepted."
  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender
Lead Sponsor
# Trials
Eli Lilly and Company
3
Alzheon Inc.
1
Biogen
1
Cassava Sciences, Inc.
1
Global Alzheimer's Platform Foundation
1
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
1
Hoffmann-La Roche
1
TauRx Therapeutics Ltd
1
Woolsey Pharmaceuticals
1
Total Rows: 9

Clinical Trials at Re:Cognition Health


During the past decade, Re:Cognition Health conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 3 clinical trials were completed, i.e. on average, 27.3% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 3 clinical trials were completed. i.e. 42.9% of trials that started reached the finish line.
Created with Highcharts 11.1.0TrialsTrials Trend - Last 10 Years113300222233000000000033Started TrialsCompleted Trails20172018201920202021202201234
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease
2018-05-03
2021-08-30
Terminated
654
A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)
2017-12-18
2021-09-21
Completed
272
Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment
2018-01-10
2023-03-01
Active, not recruiting
598
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
2018-04-30
2021-10-25
Completed
360
A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease
2020-10-27
2026-10-01
Suspended
2,046
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
2021-05-19
2024-06-30
Active, not recruiting
300
Fasudil fOr redUcing elopemeNt and Spatial Disorientation
2020-12-15
2022-02-11
Completed
24
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease
2021-11-03
2023-10-01
Recruiting
750

Rows per page:

1–11 of 11

Clinical Trials Sponsors and Collaborators


Out of the total clinical trials conducted in "Re:Cognition Health" #1 sponsor was "Eli Lilly and Company" with 3 trials, followed by "Alzheon Inc." with 1 trials sponsored, "Biogen" with 1 trials sponsored, "Cassava Sciences, Inc." with 1 trials sponsored and "Global Alzheimer's Platform Foundation" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Re:Cognition Health" #1 collaborator was "National Institute on Aging (NIA)" with 1 trials as a collaborator and "Premier Research Group plc" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.
Created with Highcharts 11.1.0Top Leading Sponsors

Created with Highcharts 11.1.0Top Collaborators

Clinical Trials Conditions at Re:Cognition Health


According to Clinical.Site data, the most researched conditions in "Re:Cognition Health" are "Alzheimer Disease" (5 trials), "Alzheimer's Disease" (2 trials), "Alzheimer Disease (AD)" (1 trials), "Alzheimers Disease" (1 trials) and "Dementia" (1 trials). Many other conditions were trialed in "Re:Cognition Health" in a lesser frequency.

Clinical Trials Intervention Types at Re:Cognition Health


Most popular intervention types in "Re:Cognition Health" are "Drug" (10 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (8 trials), "BIIB092" (1 trials), "Donanemab" (1 trials), "Experimental: ALZ-801" (1 trials) and "GV-971" (1 trials). Other intervention names were less common.

Clinical Trials Genders at Re:Cognition Health


The vast majority of trials in "Re:Cognition Health" are 11 trials for "All" genders.

Clinical Trials Status at Re:Cognition Health


Currently, there are NaN active trials in "Re:Cognition Health". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Re:Cognition Health, 1 suspended trials, and 2 terminated clinical trials to date.
Out of the total trials that were conducted in Re:Cognition Health, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".
Created with Highcharts 11.1.0Trials By Phase

Created with Highcharts 11.1.0Trials Status